-
Novartis Pharmaceuticals Corporation et al v. Breckenridge Pharmaceutical Inc. DC CAFC
- 1:14-cv-01043
- D. Del.
- Judge: Richard G. Andrews
- Filed: 08/13/2014
- Closed: 03/27/2019
- Latest Docket Entry: 04/05/2019
- PACER
2
Plaintiffs
1
Defendant
1
Accused
Product
4
Patents-in-Suit
1,688
Days in
Litigation
-
Novartis Pharmaceuticals Corporation et al v. Breckenridge Pharmaceutical Inc. DC CAFC
- 1:14-cv-01043
- D. Del.
- Judge: Richard G. Andrews
- Filed: 08/13/2014
- Closed: 03/27/2019
- Latest Docket Entry: 04/05/2019
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 7 |
A method of treating or preventing an autoimmune or inflammatory condition or transplant rejection in a subject suffering from or at risk for such condition or rejection, comprising co-administering synergistically effective amounts of (I) an IL-2
view more
|
Invalid (101 and 103)
Entry 8 |
| All Claims |
NA
|
Valid (103)
Entry 169 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 7 |
A method of treating or preventing an autoimmune or inflammatory condition or transplant rejection in a subject suffering from or at risk for such condition or rejection, comprising co-administering synergistically effective amounts of (I)
view more
|
Invalid (101 and 103)
Entry 8 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A compound of the formula ##STR3## wherein R.sup.1 is hydroxy(C.sub.1-6)alkyl or hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.
|
Invalid (101 and 103)
Entry 8 |
| 2 |
A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkyl or hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.
|
Invalid (101 and 103)
Entry 8 |
| 3 |
A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkyl.
|
Invalid (101 and 103)
Entry 8 |
| 7 |
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier therefor.
|
Invalid (101 and 103)
Entry 8 |
| 10 |
The compound according to claim 1 which is 40-O-(3-hydroxyethyl)-rapamycin.
|
Invalid (101 and 103)
Entry 8 |
-
Infringement
Breckenridge Pharmaceutical, Inc.
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.25 mg0.5mg0.75 mg dosage strength everolimus tablets | US 6,239,124 B1 |
7
|
Infringement
Entry 8
|
| 0.25 mg0.5mg0.75 mg dosage strength everolimus tablets | US 6,455,518 B2 |
7
|
Infringement
Entry 8
|
